These medications change how your body processes hunger and fullness, often making it difficult to know what, when, and how much to eat
For chronic weight management, both trizepatide (Zepbound) and semaglutide 2.4 mg (Wegovy) are indicated for adults with a BMI 30 or a BMI 27 with at least one weight-related condition (such as hypertension, dyslipidemia, type 2 diabetes, sleep apnea, or cardiovascular disease)
Notably, seven patients who initially did not produce viable oocytes successfully retrieved oocytes following L-carnitine treatment (mean age: 37.7 years, mean AMH concentration: 0.295 ng/ml)
1 GLP-1-based injectables such as Wegovy and Zepbound have redefined expectations for efficacy in weight loss, cardiovascular safety and metabolic benefits, stimulating sustained double-digit growth